NDAORALTABLET
Approved
Apr 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TINDAL (acetophenazine maleate) is an oral antipsychotic tablet approved in 1961 by Merck & Co. as a first-generation phenothiazine derivative. It is indicated for the treatment of psychotic disorders and schizophrenia, though specific indications are not detailed in current labeling. The drug works through dopamine antagonism in the central nervous system.
LOE Approaching
As a legacy antipsychotic approaching loss of exclusivity, this product likely operates with a small, stable maintenance team focused on managed care and pricing rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TINDAL offers minimal career growth opportunities given its LOE-approaching status, legacy market position, and zero linked job openings. Roles on this product are primarily maintenance-focused, emphasizing managed care navigation, pricing defense, and compliance rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on TINDAL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.